Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.60 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20213921 | 0.90 | NAMPT (0.72) | NAMPTGRM5HSP90AB1CDK4CCND1 | |
| SCHEMBL24062095 | 0.87 | NAMPT (0.47) | NAMPTGRM5HSP90AB1KDM4E | |
| SCHEMBL22915970 | 0.87 | POLB (0.55) | NAMPTGRM5CDK4CCND1L3MBTL1 | |
| SCHEMBL22915890 | 0.86 | KDM4E (0.47) | NAMPTGRM5KCNH2KDM4E | |
| SCHEMBL20214414 | 0.85 | SMN1; SMN2 (0.57) | NAMPTGRM5CDK4CCND1KCNH2 | |
| SCHEMBL22915967 | 0.85 | MAPK1 (0.50) | NAMPTCDK4CCND1L3MBTL1HTR2B | |
| Oxalic Acid SCHEMBL6423881 | 0.84 | NAMPT (0.44) | NAMPTGRM5HSP90AB1KDM4E | |
| SCHEMBL22915934 | 0.84 | HPGD (0.51) | NAMPTL3MBTL1GABRA1GABRA2 | |
| Oxalic Acid SCHEMBL6425330 | 0.83 | MEN1 (0.47) | NAMPTKCNH2 | |
| SCHEMBL22915972 | 0.83 | NAMPT (0.48) | NAMPTGRM5CDK4CCND1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | NAMPT 1158/4885GRM5 540/4885HSP90AB1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.